NewLink Genetics Corp. Company Profile (NASDAQ:NLNK)

About NewLink Genetics Corp.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: NLNK
CUSIP: 65151110

Key Metrics:

Previous Close: $15.02
50 Day Moving Average: $10.93
200 Day Moving Average: $12.87
52-Week Range: $9.23 - $46.34
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -9.27
P/E Growth: 0.00
Market Cap: $435.11M
Outstanding Shares: 28,969,000
Beta: 1.13

Profitability:

Net Margins: -316.38%
Return on Equity: -51.33%
Return on Assets: -45.39%

Debt:

Current Ratio: 7.63%
Quick Ratio: 7.63%

Additional Links:

Companies Related to NewLink Genetics Corp.:

Consensus Ratings for NewLink Genetics Corp. (NASDAQ:NLNK) (?)

Ratings Breakdown:	2 Hold Ratings, 4 Buy Ratings
Consensus Rating:	Buy (Score: 2.67)
Consensus Price Target:	$25.00 (66.44% upside)

Analysts' Ratings History for NewLink Genetics Corp. (NASDAQ:NLNK)

Show:

Date	Firm	Action	Rating	Price Target
5/16/2016	Robert W. Baird	Reiterated Rating	Buy
5/11/2016	Jefferies Group	Reiterated Rating	Hold	$10.00
5/10/2016	SunTrust Banks Inc.	Downgrade	Buy -> Neutral	$59.00 -> $12.00
5/10/2016	Mizuho	Lower Price Target	Buy	$52.00 -> $20.00
5/10/2016	Stifel Nicolaus	Lower Price Target	Buy	$63.00 -> $23.00
4/29/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$62.00

(Data available from 10/1/2014 forward)

Earnings History for NewLink Genetics Corp. (NASDAQ:NLNK)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/1/2016
7/29/2016	Q216	($0.77)	($1.12)	$5.41 million		View	Listen
4/29/2016	Q116	($1.70)	($0.82)	$2.08 million	$4.34 million	View	Listen
2/29/2016	Q415	($0.92)	($0.75)	$4.89 million	$6.06 million	View	Listen
11/3/2015	Q315	($0.66)	($0.55)	$6.76 million		View	N/A
7/31/2015	Q215	($0.70)	($0.49)	$4.32 million	$7.45 million	View	Listen
5/5/2015	Q115	($0.22)	$0.35	$2.32 million		View	N/A
2/26/2015	Q414	($0.68)	$4.05	$2.98 million	$159.25 million	View	N/A
11/6/2014	Q314	($0.40)	($0.20)		$2.80 million	View	N/A
8/5/2014	Q214	($0.42)	($0.33)			View	N/A
5/6/2014		($0.37)	($0.33)			View	N/A
3/11/2014		($0.37)	($0.31)			View	N/A
11/11/2013	Q3	($0.33)	($0.32)			View	N/A
8/7/2013	Q213	($0.32)	($0.28)	$0.59 million	$0.23 million	View	N/A
5/6/2013	Q113	($0.28)	($0.33)	$0.41 million	$0.30 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for NewLink Genetics Corp. (NASDAQ:NLNK)

Current Year EPS Consensus Estimate: $-3.16 EPS
Next Year EPS Consensus Estimate: $-1.62 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	($0.92)	($0.87)	($0.90)
Q2 2016	2	($0.89)	($0.80)	($0.85)
Q3 2016	2	($0.84)	($0.69)	($0.77)
Q4 2016	2	($0.66)	($0.59)	($0.63)

(Data provided by Zacks Investment Research)

Dividend History for NewLink Genetics Corp. (NASDAQ:NLNK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for NewLink Genetics Corp. (NASDAQ:NLNK)

Insider Ownership Percentage: 12.00%
Institutional Ownership Percentage: 50.10%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/15/2016	Charles J Jr. Link	CEO	Sell	25,000	$17.86	$446,500.00
1/6/2016	Charles J. Jr. Link	CEO	Sell	25,000	$32.53	$813,250.00
1/5/2016	Brian Wiley	VP	Sell	1,295	$34.99	$45,312.05
1/5/2016	Carl W. Langren	insider	Sell	1,095	$34.97	$38,292.15
1/5/2016	Charles J. Jr. Link	CEO	Sell	5,001	$35.06	$175,335.06
1/5/2016	John B. Henneman III	CFO	Sell	175	$35.74	$6,254.50
10/7/2015	Charles J. Jr. Link	CEO	Sell	10,000	$35.16	$351,600.00
10/5/2015	Charles J. Jr. Link	CEO	Sell	15,000	$37.36	$560,400.00
7/13/2015	Joseph Saluri	Director	Sell	5,000	$50.42	$252,100.00
7/6/2015	Charles J Jr. Link	CEO	Sell	20,000	$44.65	$893,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for NewLink Genetics Corp. (NASDAQ:NLNK)

Date	Headline
	NewLink Genetics Corporation (NLNK) Updated Broker Price Targets - The De Soto Edge (NASDAQ:NLNK) desotoedge.com - September 29 at 11:34 AM
	Today's Pattern Alert: After Forming Multiple Bottom Chart Pattern, Is NewLink Genetics Corp's Near-Term Analysis ... - Chester News (NASDAQ:NLNK) www.chesterindependent.com - September 29 at 11:34 AM
	NewLink Genetics Has Many Near-Term Catalysts - Seeking Alpha (NASDAQ:NLNK) seekingalpha.com - September 29 at 11:34 AM
	ETF’s with exposure to NewLink Genetics Corp. : September 29, 2016 (NASDAQ:NLNK) www.capitalcube.com - September 29 at 11:34 AM
	Notable Wednesday Option Activity: XOM, OPHT, NLNK (NASDAQ:NLNK) www.marketnewsvideo.com - September 28 at 6:09 PM
	NewLink Genetics Has Many Near-Term Catalysts (NASDAQ:NLNK) seekingalpha.com - September 27 at 6:16 PM
	Biotechnology Sector Developments in Cancer Therapy (NASDAQ:NLNK) www.biomedreports.com - September 26 at 6:29 PM
	The Bioscience and Biotechnology Sector Developments in Cancer Therapy - PR Newswire (press release) (NASDAQ:NLNK) www.prnewswire.com - September 26 at 11:06 AM
	Strength Seen in NewLink Genetics (NLNK): Stock Jumps 5% (NASDAQ:NLNK) finance.yahoo.com - September 26 at 11:06 AM
	Chart of The Day: NewLink Genetics Corp Formed a Multiple Bottom, Could Be One of The Worst Performers Going ... - Chester News (NASDAQ:NLNK) www.chesterindependent.com - September 19 at 6:25 PM
	NewLink Genetics Corp. – Value Analysis (NASDAQ:NLNK) : September 19, 2016 (NASDAQ:NLNK) www.capitalcube.com - September 19 at 6:25 PM
	What are Brokerage Firms Saying About NewLink Genetics Corporation (NASDAQ:NLNK)? - Frisco Fastball (NASDAQ:NLNK) friscofastball.com - September 18 at 5:59 PM
	Looking Ahead for NewLink Genetics Corporation (NASDAQ:NLNK); Are These Shares Ready to Go Higher? - Frisco Fastball (NASDAQ:NLNK) friscofastball.com - September 18 at 5:59 PM
	NewLink Genetics Corp. breached its 50 day moving average in a Bullish Manner : NLNK-US : September 16, 2016 (NASDAQ:NLNK) www.capitalcube.com - September 16 at 9:55 AM
	ETF’s with exposure to NewLink Genetics Corp. : September 9, 2016 (NASDAQ:NLNK) www.capitalcube.com - September 9 at 6:04 PM
	NewLink Genetics to Participate in Baird Healthcare Conference - GlobeNewswire (press release) (NASDAQ:NLNK) globenewswire.com - September 3 at 10:45 AM
	NewLink Genetics to Participate in Baird Healthcare Conference (NASDAQ:NLNK) finance.yahoo.com - September 1 at 9:36 AM
	ETF’s with exposure to NewLink Genetics Corp. : August 22, 2016 (NASDAQ:NLNK) www.capitalcube.com - August 22 at 6:25 PM
	Stock Tracking Lower for the Quarter: NewLink Genetics Corporation (NASDAQ:NLNK) - Post News (NASDAQ:NLNK) www.kentuckypostnews.com - August 20 at 6:08 PM
	NEWLINK GENETICS CORP Financials (NASDAQ:NLNK) finance.yahoo.com - August 13 at 6:09 PM
	ETF’s with exposure to NewLink Genetics Corp. : August 8, 2016 (NASDAQ:NLNK) www.capitalcube.com - August 8 at 6:41 PM
	NewLink Genetics Corporation (NLNK) Shares are Up 3.97% - Trade Calls (NASDAQ:NLNK) www.tradecalls.org - August 8 at 11:10 AM
	Revenue Update on NewLink Genetics Corp(NASDAQ:NLNK) - Trade Calls (NASDAQ:NLNK) www.tradecalls.org - August 7 at 6:05 PM
	NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:NLNK) www.capitalcube.com - August 5 at 6:39 PM
	NEWLINK GENETICS CORP Files SEC form 10-Q, Quarterly Report (NASDAQ:NLNK) biz.yahoo.com - August 5 at 6:39 PM
	NewLink Genetics Corporation: NewLink Genetics Reports Second Quarter 2016 Financial Results (NASDAQ:NLNK) www.twst.com - July 30 at 9:19 AM
	NewLink reports 2Q loss (NASDAQ:NLNK) www.cnbc.com - July 29 at 6:37 PM
	NewLink Genetics : reports 2Q loss (NASDAQ:NLNK) www.4-traders.com - July 29 at 6:37 PM
	NewLink Genetics (NLNK) Misses Q2 EPS by 35c; Announces Restructuring Plans (NASDAQ:NLNK) www.streetinsider.com - July 29 at 6:37 PM
	NewLink Genetics' (NLNK) CEO Charles Link on Q2 2016 Results - Earnings Call Transcript (NASDAQ:NLNK) seekingalpha.com - July 29 at 6:37 PM
	NewLink Genetics Reports Second Quarter 2016 Financial Results (NASDAQ:NLNK) www.publicnow.com - July 29 at 8:28 AM
	NEWLINK GENETICS CORP Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:NLNK) biz.yahoo.com - July 29 at 8:24 AM
	It's Earnings Time: What to Do with NewLink Genetics Corporation (NASDAQ:NLNK) Stock - The Voice Registrar (NASDAQ:NLNK) voiceregistrar.com - July 28 at 9:40 AM
	Why Earnings Season Could Be Great for NewLink Genetics (NLNK) (NASDAQ:NLNK) www.zacks.com - July 27 at 9:28 AM
	NewLink Genetics (NLNK) Announces Achievement of Two Ebola Zaire Vaccine Candidate Milestones by Merck (MRK) (NASDAQ:NLNK) www.streetinsider.com - July 26 at 9:41 AM
	NewLink Genetics (NLNK) Announces Achievement of Two Ebola Zaire Vaccine Candidate Milestones by Merck (MRK) - StreetInsider.com (NASDAQ:NLNK) www.streetinsider.com - July 25 at 10:54 AM
	NewLink Genetics Announces Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920) (NASDAQ:NLNK) www.publicnow.com - July 25 at 8:18 AM
	NewLink Genetics Corp. breached its 50 day moving average in a Bearish Manner : NLNK-US : July 22, 2016 (NASDAQ:NLNK) www.capitalcube.com - July 22 at 8:23 AM
	NewLink Genetics Corporation (NASDAQ:NLNK): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:NLNK) www.engelwooddaily.com - July 21 at 6:45 PM
	Newlink Genetics Corporation (NASDAQ:NLNK) Sellers Covered 19.5% of Their Shorts - Consumer Eagle (NASDAQ:NLNK) www.consumereagle.com - July 21 at 6:45 PM
	NewLink Genetics Corporation (NLNK) Drops 5.14% on July 19 - Equities.com (NASDAQ:NLNK) www.equities.com - July 21 at 6:45 PM
	Equity Roundup: Stock Performance Focus on NewLink Genetics Corporation (NASDAQ:NLNK) - Press Telegraph (NASDAQ:NLNK) presstelegraph.com - July 20 at 9:25 AM
	NewLink Genetics to Host Its Second Quarter 2016 Financial Results Conference Call on July 29, 2016 (NASDAQ:NLNK) finance.yahoo.com - July 20 at 7:00 AM
	Earnings Focus and Crowd Sourced Sentiment Review for NewLink Genetics Corporation (NASDAQ:NLNK) - TGP (NASDAQ:NLNK) telanaganapress.com - July 19 at 6:36 PM
	NewLink Genetics Corp. – Value Analysis (NASDAQ:NLNK) : July 18, 2016 (NASDAQ:NLNK) www.capitalcube.com - July 18 at 4:04 PM
	NewLink Genetics Corporation (NLNK) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:NLNK) www.fiscalstandard.com - July 17 at 10:42 AM
	Shares Experiencing a Downtrend: NewLink Genetics Corporation (NASDAQ:NLNK) - TGP (NASDAQ:NLNK) telanaganapress.com - July 15 at 5:29 PM
	Analyst Target and Average Rating Watch: NewLink Genetics Corporation (NASDAQ:NLNK) - Press Telegraph (NASDAQ:NLNK) presstelegraph.com - July 15 at 11:17 AM
	NewLink Genetics Corporation (NASDAQ:NLNK) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:NLNK) www.engelwooddaily.com - July 15 at 11:17 AM
	Are Analysts Bearish NewLink Genetics Corp (NASDAQ:NLNK) After Last Week? - Consumer Eagle (NASDAQ:NLNK) www.consumereagle.com - July 15 at 11:17 AM